International Clinical Trial: Safety and Efficacy of Obinutuzumab-ß for MOG Antibody-Positive Optic Neuritis

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132519) titled 'Safety and Efficacy of Obinutuzumab-ß for MOG Antibody-Positive Optic Neuritis' on Sept. 15.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Eye Hospital, Wenzhou Medical University

Condition: myelin oligodendrocyte glycoprotein antibody-positive optic neuritis

Intervention: control group:Methylprednisolone 1000 mg was administered by intravenous infusion for 3 days, followed by 500 mg by intravenous infusion for 3 days treatment was then switched to oral prednisone at 60 mg/day, with the dose reduced by 5 mg weekly until reaching 10 mg/day, at which point the dose was mainta...